

Role of Leptin and Other Adipokines in HIV Infection and HIV-related Obesity

**John Koethe MD, MSCI
Vanderbilt University Medical Center
Division of Infectious Diseases**

**National Institutes of Health
Obesity and Fat Metabolism in HIV-infected Individuals Workshop
May 22 and 23, 2018**




Disclosures

John Koethe receives research funding from Gilead Pharmaceuticals

Adipokines: peptides signaling the energy storage status of adipose tissue to brain, and other organs.

- Leptin
- Adiponectin
- Visfatin/Nampt/PBEF
- Vaspin
- RBP4
- FGF21
- BMPs
- Nesfatin-1
- Cathepsins
- Apelin
- Omentin
- Lipocalin
- and hundreds more


Adipokines inform the body that sufficient energy is available to mount a given response, or that limited energy availability should constrain the response



Relative adipokine production shifts with progressive obesity


Lean

Inflammation controlled
Metabolic function intact




Obese 'Healthy'

↑ Inflammation
↓ Metabolic function



Obese 'Unhealthy'

↑↑ Inflammation
↓↓ Metabolic function



'Lean adipokines'

- Adiponectin
- Secreted frizzled-related protein 5 (Sfrp5)

'Obese adipokines'

- Leptin
- Retinol binding protein-4 (RBP4)
- Resistin

Adipocyte hypertrophy

- IL-6
- TNF- α
- MCP-1

Adiponectin and leptin balance central to regulating multiple biological processes

Adiponectin

- Increases in lean states, falls precipitously with visceral obesity (a *Hormone of Starvation*)
- Stimulates food intake and suppresses energy expenditure
- Sensitizes liver and muscle to insulin
- Anti-atherogenic (reduces endothelial activation, prevents foam cell formation and plaque T cell entry)
- Adipose paracrine activity:
 - Promotes M2 macrophage phenotype, clearance of apoptotic debris
 - Reduces T cell infiltration, activation
 - Promotes adipocyte hyperplasia

Leptin

- Circulates in proportion to fat mass (a *Hormone of Plenty*)
- Serves as indicator of global energy stores
- Reduces appetite and increases activity
- Receptors are widely expressed (CNS, immune, CV, hepatic, GI and other tissues) – A *rheostat* for many processes
- Broad immune effects:
 - Innate immune cell proliferation/activation
 - T and B cell proliferation and survival
 - T_H1 polarization

Adiponectin and leptin: a delicate balance regulating immune activity



Low leptin / high adiponectin

- Malnutrition
- Leptin and leptin receptor deficits




Normal leptin & adiponectin

- Appropriate energy stores



High leptin / low adiponectin

- Obesity



Reduced response to antigen, proliferation, and activation to conserve energy

Appropriate response to antigen, normal cell survival, de-escalation after threat resolved

Lower barrier to cellular activation, high proliferation, robust cytokine production, impaired de-escalation

Conserved physiologic role



Low leptin / high adiponectin

- Malnutrition
- Leptin and leptin receptor deficits

Normal leptin & adiponectin

- Appropriate energy stores

High leptin / low adiponectin

- Obesity

Reduced response to antigen, proliferation, and activation to conserve energy

Appropriate response to antigen, normal cell survival, de-escalation after threat resolved

Lower barrier to cellular activation, high proliferation, robust cytokine production, impaired de-escalation

The World in 2018



Low leptin / high adiponectin

- Malnutrition
- Leptin and leptin receptor deficits

Normal leptin & adiponectin

- Appropriate energy stores

High leptin / low adiponectin

- Obesity

Reduced response to antigen, proliferation, and activation to conserve energy


Appropriate response to antigen, normal cell survival, de-escalation after threat resolved

Lower barrier to cellular activation, high proliferation, robust cytokine production, impaired de-escalation

Highlights of leptin effects on innate immunity

Neutrophils:


- Reduced apoptosis
- Increased phagocytic activity
- Enhanced CD11b expression



Highlights of leptin effects on innate immunity

Monocytes/macrophages:

- Increased of phagocytic function
- Increased adhesion molecules
- Increased proliferation and activation marker expression (CD25, CD69)
- Increased TNF- α and IL-6 expression
- May serve as a chemoattractant in adipose tissue




Highlights of leptin effects on innate immunity

Dendritic cells:

- Reduced apoptosis
- Shift towards T_H1 priming
- Increased TNF- α , IL-6, IL-8 production

Eosinophils:


- Reduced apoptosis
- Increased activation
- Increased chemotaxis, migration, and adhesion molecule expression



Highlights of leptin effects on adaptive immunity

T cells:


- Increases proliferation of naïve cells
- Activation of CD4+ T cells markedly increases leptin receptor expression (less on CD8+ T cells)
- Increases adhesion molecule expression and activation markers (CD69, CD25, CD71)




Highlights of leptin effects on adaptive immunity

T cells:

- Promotes expansion of activated CD4+ and CD8+ T cells
- Promotes polarization towards T_H1/T_H17 responses (sustained by autocrine loop of leptin secretion)
- Increased INF- γ , TNF- α expression
- Reduced Treg cell proliferation




CD8+ T cells in adipose tissue are more clonal compared to blood in HIV+ persons



- The 10 most prevalent T cell receptors comprise a larger percentage of the total repertoire in adipose tissue compared to paired blood (25% vs. 16%)


CD4+ T cell subsets in adipose tissue from HIV+ persons is enriched for effector memory cells




BMI and HIV progression in the pre-combination ART era

- A BMI ≥ 30 kg/m² was associated with a slower progression to a CD4 <200, AIDS-defining event or HIV-related death compared to a BMI 20-25 kg/m²
- Each 1 kg/m² reduction in initial BMI was independently associated with a 24% increased risk of progression to AIDS over mean follow-up of 19 months

Higher time-updated BMI accompanied by greater CD4+ T cell recovery on ART



Higher time-updated BMI accompanied by greater CD4+ T cell recovery on ART



Could there be a role for leptin promoting immune recovery and/or response to opportunistic infections in HIV+ persons?

Recombinant leptin trials in HIV-negative children

- ▶ A 3-year-old boy with congenital leptin deficiency (*ob⁻/ob⁻*)
- ▶ Weight 42kg before treatment with recombinant leptin
- ▶ Weight 32kg after 4 years of treatment



**Before leptin
(age 3, 42 kg)**



**After leptin
(age 7, 32 kg)**

Recombinant leptin trials in HIV-negative children

Proliferative responses of PBMCs to T-cell stimuli before and after leptin treatment

Cell type	-6 months	Treatment start	+2 months	+6 months	+10 months	Normal range (child age 3; cells/mm ³)
CD3+ (%)	2,686 (49%)	2,416 (58)	1,893 (51)	3,262 (72)	3,087 (66)	1,200-2,500 (65-82%)
CD4+ (%)	750 (18%)	866 (21)	927 (24)	1,468 (31)	1,358 (29)	1,000-2,000 (30-50%)
CD8+ (%)	1,836 (26%)	1,450 (25)	850 (22)	1,468 (31)	1,543 (33)	240-1,000 (25-35%)
CD19+ (%)	2,189 (31%)	1,525 (37)	1,468 (38)	1,247 (26)	1,216 (26)	200-400 (8-15%)


Recombinant leptin trials in HIV-negative children

Proliferative responses of PBMCs to T-cell stimuli before and after leptin treatment

Cell type	-6 months	Treatment start	+2 months	+6 months	+10 months	Normal range (child age 3; cells/mm ³)
CD3+ (%)	2,686 (49%)	2,416 (58)	1,893 (51)	3,262 (72)	3,087 (66)	1,200-2,500 (65-82%)
CD4+ (%)	750 (18%)	866 (21)	927 (24)	1,468 (31)	1,358 (29)	1,000-2,000 (30-50%)
CD8+ (%)	1,836 (26%)	1,450 (25)	850 (22)	1,468 (31)	1,543 (33)	240-1,000 (25-35%)
CD19+ (%)	2,189 (31%)	1,525 (37)	1,468 (38)	1,247 (26)	1,216 (26)	200-400 (8-15%)



Recombinant leptin trials in HIV-negative children

Proliferative responses of PBMCs to T-cell stimuli before and after leptin treatment



Recombinant leptin trials in HIV-negative children

Cytokine responses of PBMCs to T-cell stimuli before and after leptin treatment



Recombinant leptin trials in HIV-associated lipodystrophy - summary

Study (year)	Design	Subjects & Duration	Change in leptin levels (ng/ml)	Beneficial effect on			Adverse effects
				Glucose metabolism	Lipid metabolism	Steatohepatitis	
Lee <i>et al.</i> (2006)	Randomized crossover	7 M (LD-HIV) 4 months	1.34 to NR	+	+	–	None major
Mulligan <i>et al.</i> (2009)	Prospective open-label	8 M (LD-HIV) 6 months	2.7–21.3	+	++	NR	None Major
Magkos <i>et al.</i> (2011)	Double blind placebo controlled	9 M (LD-HIV) 3 months	3.7–16.5	+	–	+	Injection site reaction (1)
Sekhar <i>et al.</i> (2012)	Double-blind placebo controlled	17 M (LD-HIV) 4 months	2.6–34.4	+	improved non-HDL-C, no change in lipid kinetics	NR	Weight loss (2), decline in CD4 ⁺ T-cell count (1)

No significant improvements in CD4⁺ T cell count in these studies

Potential future research areas

- Use of recombinant leptin to boost CD4 recovery or response to opportunistic infections among malnourished (e.g., BMI <18.5 kg/m²) persons in resource-limited settings.
- HIV+ persons have a high adipose CD8+ cells and low CD4+, as seen in obesity, but less macrophage activation and CD4+ subset changes. Are lower tissue leptin levels a factor in this disparity between HIV and obesity?
- Will there be a potential role for *AdipRon* (new, oral adiponectin-receptor agonist) in persons with HIV – either for improving insulin sensitivity or reducing immune activation?

Acknowledgements

Vanderbilt Center for Translational Immunology and Infectious Disease

Simon Mallal, MBBS

Spyros Kalams, MD

Elizabeth Philips, MD

Wyatt McDonnell, BS

Celestine Wanjalla, MD, PhD

Briana Furch, MD, MPH

Mark Pilkinton, MD, PhD

Rama Gangula

Ian Setliff, BS

Hasty Laboratory

Alyssa Hasty, PhD

Arion Kennedy, PhD

Marnie Gruen, BS

Tennessee Center for AIDS Research Laboratory Sciences Core

Cindy Hager, BS

Louise Barnett, BS

Rita Smith, BS

Vanderbilt Technologies for Advanced Genomics (VANTAGE)

Olivia Koues, PhD

Matt Scholtz, PhD

Paxton Baker, BS

Project funding

•NIDDK R01DK112262

•NIDDK R56DK108352


•NIAID P30 AI110527 (TN CFAR)




Thank you


VANDERBILT  UNIVERSITY
MEDICAL CENTER







Outline

- Pleiotropic effects of adipokines
 - Adipokines and immune function
 - Recombinant human leptin in HIV+ and HIV-negative person
 - Research gaps and possible future studies
- 

Adipokines and hsCRP in HIV+ persons

- Cross-sectional study of 106 HIV+ adults on >24 weeks of ART
- BMI range from <20 to >35 kg/m²

Relationship of serum adipokine levels and hsCRP level		
	β (95% CI)	Adjusted P value
Leptin	1.95 (1.36, 2.80)	<0.001
Adiponectin	0.74 (0.45, 1.21)	0.23
Resistin	1.27 (0.90, 1.80)	0.18

Models adjusted for age, sex, CD4+ lymphocyte count (in 100 cell/uL strata), smoking status, and non-steroidal anti-inflammatory drug, aspirin, and protease inhibitor use.

Adipokines and hsCRP in HIV+ persons

Body composition variable	Without adjustment for leptin		With adjustment for leptin	
	β_1	P value	β_2	P value
Body mass index	1.57	0.02	1.22	0.54
Waist-to-hip ratio	1.58	<0.01	1.22	0.03
Limb fat	1.82	0.05	1.10	0.85
Total body fat	2.16	<0.01	1.41	0.50
Total body % fat	2.45	<0.01	1.62	0.31
Trunk fat	2.55	<0.01	1.83	0.21
Trunk % fat	2.88	<0.01	2.04	0.12

Leptin mediated the relationship of BMI and DEXA absolute limb fat, body fat, and trunk fat with circulating hsCRP